
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT
- About


Senseonics Holdings Inc (SENS)



- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)


(see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
07/11/2025: SENS (5-star) is currently NOT-A-BUY. Pass it for now.
1 Year Target Price $1.55
1 Year Target Price $1.55
1 | Strong Buy |
1 | Buy |
1 | Hold |
1 | Sell |
0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 57.77% | Avg. Invested days 27 | Today’s Advisory PASS |
Upturn Star Rating ![]() ![]() | Upturn Advisory Performance ![]() | Stock Returns Performance ![]() |
![]() ![]() | ![]() ![]() |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 402.40M USD | Price to earnings Ratio - | 1Y Target Price 1.55 |
Price to earnings Ratio - | 1Y Target Price 1.55 | ||
Volume (30-day avg) 4 | Beta 0.99 | 52 Weeks Range 0.25 - 1.40 | Updated Date 07/13/2025 |
52 Weeks Range 0.25 - 1.40 | Updated Date 07/13/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.11 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -215.57% |
Management Effectiveness
Return on Assets (TTM) -41% | Return on Equity (TTM) -161.19% |
Valuation
Trailing PE - | Forward PE 21.51 | Enterprise Value 379242708 | Price to Sales(TTM) 16.99 |
Enterprise Value 379242708 | Price to Sales(TTM) 16.99 | ||
Enterprise Value to Revenue 16.01 | Enterprise Value to EBITDA 1.76 | Shares Outstanding 809830016 | Shares Floating 599788651 |
Shares Outstanding 809830016 | Shares Floating 599788651 | ||
Percent Insiders 8.89 | Percent Institutions 10.96 |
Upturn AI SWOT
Senseonics Holdings Inc

Company Overview
History and Background
Senseonics Holdings, Inc. was founded in 2003. It focuses on the design, development, and commercialization of glucose monitoring systems, primarily continuous glucose monitoring (CGM) systems for people with diabetes. Its initial focus was on developing long-term implantable CGM systems. Over the years, it has achieved FDA approvals for its Eversense and Eversense E3 systems.
Core Business Areas
- Continuous Glucose Monitoring (CGM) Systems: The core of Senseonics' business is the development and sale of its Eversense CGM systems, which include an implantable sensor, a smart transmitter, and a mobile app for data monitoring.
Leadership and Structure
The company has a leadership team including a CEO, CFO, and other key executives responsible for different aspects of the business such as research and development, sales, and marketing. The organizational structure typically involves departments for research, product development, sales, marketing, regulatory affairs, and finance.
Top Products and Market Share
Key Offerings
- Eversense CGM System: The Eversense CGM System features a small sensor implanted under the skin that measures glucose levels continuously for up to 180 days (Eversense) or 365 days (Eversense E3), depending on the specific version. The system also includes a smart transmitter worn on the arm and a mobile app for real-time glucose monitoring and alerts. Market share data is volatile but typically ranges between 1-3% of the total CGM market. Competitors include Dexcom (DXCM) and Abbott Laboratories (ABT) which have the FreeStyle Libre line.
- Eversense E3 CGM System: The next-generation implantable CGM system with sensor life up to 365 days. This system offers the same functionality as the original Eversense system with a longer sensor life. Market share is included within the overall Eversense CGM numbers. Competitors include Dexcom (DXCM) and Abbott Laboratories (ABT) which have the FreeStyle Libre line.
Market Dynamics
Industry Overview
The glucose monitoring market is driven by the increasing prevalence of diabetes, technological advancements in CGM systems, and growing patient demand for more convenient and accurate monitoring solutions. The industry is highly competitive, with established players and emerging companies vying for market share.
Positioning
Senseonics is positioned as a provider of long-term implantable CGM systems, differentiating itself from competitors offering traditional CGM systems that require frequent sensor replacements. Its competitive advantage lies in the convenience of long-term monitoring and reduced insertion frequency.
Total Addressable Market (TAM)
The global CGM market is expected to reach tens of billions of USD within the next 5-7 years. Senseonics is attempting to carve out a share of this market with its long term and next generation technologies.
Upturn SWOT Analysis
Strengths
- Long-term implantable sensor
- Reduced insertion frequency
- Potential for improved patient adherence
- Proprietary technology
Weaknesses
- Higher initial cost
- Surgical insertion required
- Reliance on partner (Ascensia) for distribution and sales
- Limited market share compared to competitors
Opportunities
- Expanding partnerships
- Further technological advancements in sensor life and accuracy
- Increased adoption of CGM systems
- Potential for use in non-diabetic populations
Threats
- Competition from established CGM providers (Dexcom, Abbott)
- Reimbursement challenges
- Potential for adverse events related to sensor implantation
- Technological disruption from new glucose monitoring methods
Competitors and Market Share
Key Competitors
- DXCM
- ABT
Competitive Landscape
Senseonics' long-term implantable sensor provides a competitive advantage over traditional CGM systems. However, it faces challenges from established players with greater market share and resources. Success depends on driving adoption, securing reimbursement, and demonstrating the clinical benefits of its technology.
Growth Trajectory and Initiatives
Historical Growth: Senseonics' historical growth has been characterized by periods of rapid expansion followed by periods of market adoption challenges. Reimbursement and sales execution have impacted growth.
Future Projections: Future growth projections are uncertain and depend on factors such as regulatory approvals, market adoption, and competition. Consult analyst reports for revenue estimates.
Recent Initiatives: Recent initiatives include partnerships with Ascensia Diabetes Care for commercialization, advancements in sensor technology (e.g., Eversense E3), and efforts to expand market access through reimbursement coverage.
Summary
Senseonics offers a unique long-term implantable CGM system that differentiates it from competitors. While its technology is innovative, it faces challenges related to market adoption, reimbursement, and competition. Successful execution of its commercialization strategy and continued technological advancements are crucial for future growth. Recent initiatives with Ascensia Diabetes Care could prove beneficial. Investors should monitor the company's progress in securing reimbursement coverage and driving sales growth.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company filings
- Analyst reports
- Industry publications
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. Market share estimates are approximate and may vary. Financial data is subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Senseonics Holdings Inc
Exchange NYSE MKT | Headquaters Germantown, MD, United States | ||
IPO Launch date 2016-03-17 | President, CEO & Director Dr. Timothy T. Goodnow Ph.D. | ||
Sector Healthcare | Industry Medical Devices | Full time employees 117 | Website https://www.senseonics.com |
Full time employees 117 | Website https://www.senseonics.com |
Senseonics Holdings, Inc., a commercial-stage medical technology company, focuses on development and manufacturing of continuous glucose monitoring (CGM) systems for people with diabetes in the United States and internationally. The company's products include Eversense, Eversense XL, Eversense E3, and Eversense 365, which are implantable CGM systems to measure glucose levels in people with diabetes through an under-the-skin sensor, a removable and rechargeable smart transmitter, and an app for real-time diabetes monitoring and management. It serves healthcare providers and patients through a network of distributors and strategic fulfillment partners. The company was founded in 1996 and is headquartered in Germantown, Maryland.

Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.